News release
Henry Mayo Newhall Hospital is one of the first hospitals in Southern California to improve treatment of “widowmaker” heart attack patients with SuperSaturated Oxygen Therapy, the first and only Food and Drug Administration-approved therapy that could reduce muscle damage in heart attack patients after percutaneous intervention, according to a news release from the hospital.
SSO2 therapy is an innovative treatment designed to reduce heart muscle damage after a severe heart attack, also known as a ST-elevation myocardial infarction, the release said. This FDA-approved therapy delivers super-oxygenated blood directly to the affected area, enhancing recovery and improving patient outcomes, according to the release.
Studies have shown that SSO2 therapy can reduce heart damage and scarring in “widowmaker” heart patients, which is directly linked to lower risks of heart failure and other long-term complications, the release said.
“The introduction of SSO2 therapy at Henry Mayo is a game-changer for certain heart attack patients,” Jennifer Whitcomb, senior director of Perioperative and Cardiovascular Services at HMNH, said in the release. “By incorporating this advanced therapy, we are offering our community access to one of the most promising treatments available for reducing heart damage and improving long-term heart function.”
The Roberta G. Veloz Cardiovascular Center offers an array of cardiac services, including interventional cardiology, electrophysiology, structural heart procedures and more.
SSO2 Therapy was developed by Irvine-based ZOLL TherOx and is the first and only FDA-approved treatment beyond percutaneous coronary intervention to significantly reduce muscle damage in heart attack patients, the release said. Additional information about SSO2 Therapy is available at www.TherOx.com.
For more information about Henry Mayo Newhall Hospital’s cardiovascular services, visit henrymayo.com/heart.
